Loading...
Loading...
ADCT| Name | Value |
|---|---|
| Revenues | 69.8M |
| Cost of Revenue | 0.5M |
| Gross Profit | 69.3M |
| Operating Expense | 80.0M |
| Operating I/L | -10.7M |
| Other Income/Expense | -9.5M |
| Interest Income | 1.6M |
| Pretax | -20.2M |
| Income Tax Expense | 4.0M |
| Net Income/Loss | -24.2M |
ADC Therapeutics SA is a biotechnology company specializing in the development of antibody drug conjugates (ADC) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is undergoing clinical trials for the treatment of various lymphomas, while camidanlumab tesirine is being developed for NHL and hodgkin lymphoma. The company also has several other product candidates in different stages of clinical trials for the treatment of leukemia and solid tumors. ADC Therapeutics generates revenue through the development and commercialization of these innovative ADC therapies, and it has collaboration and license agreements with several pharmaceutical companies.
